NCT04089449View on ClinicalTrials.gov

A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions
Advanced Solid TumorRecurrent Glioma
Interventions
DRUG

PRT811

PRT811 will be administered orally

Trial Locations (11)

19107

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

19718

Christiana Care Health Services, Christiana Hospital, Newark

30912

Georgia Cancer Center at Augusta University, Augusta

32746

Florida Cancer Specialists, Lake Mary

37203

Tennessee Oncology, Nashville

43210

The Ohio State University and Wexner Medical Center, Columbus

52242

University of Iowa Hospitals and Clinics, Iowa City

60611

Northwestern Memorial Hospital, Chicago

63110

Washington University School of Medicine - Siteman Cancer Center, St Louis

80218

Sarah Cannon Research Institute at HealthONE, Denver

06510

Yale- New Haven Hospital- Yale Cancer Center, New Haven

Sponsors
All Listed Sponsors
lead

Prelude Therapeutics

INDUSTRY

NCT04089449 - A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas | Biotech Hunter | Biotech Hunter